Duopharma likely to see earnings recovery in 4Q

Duopharma Biotech Bhd's new plant will cater for the production of biotech injectable products such as Erythropoietin injection.

PETALING JAYA: Duopharma Biotech Bhd will likely see an earnings recovery from the fourth quarter of 2023 (4Q23) as sales recover on improved demand.

For perspective, the contract period of the pharmaceutical company’s agreement for the supply of Approved Products Purchase List (APPL) products has been further extended to Dec 31, 2023.